Publications

co-investigators, key personnel, or other significant contributors in this proposed study

A Potential Biomarker of Interstitial Cystitis

Alpha-Oxoglutarate, Perturbates Epigenetic Landscapes and Biology of Bladder Epithelial Cells, 108th Annual Meeting of the Japanese Urological Association (oral presentation), April 23-26, 2020, Kobe, Japan. – Reschedule in Dec 22-24, 2020

Metabolomic Assessment of Interstitial Cystitis Serum and Urine Reveals Diagnostic Utility, in review

Kim J, Hoedt AD, Wiggins E, Haywood K, Jin P, Greenwood B, Narain NR, Tolstikov V, Bussberg V, Kiebish MA, Freedland S, Anger J (2020) Metabolomic Assessment of Interstitial Cystitis Serum and Urine Reveals Diagnostic Utility, in review

Variation in symptoms experienced by women with Interstitial Cystitis

Tholemeier VN, Wiggins E, Dallas KB, Bresee CT, De Hoedt A, Senechal JF, Barbour KE, Kim J, Freedland SF, Anger JT, Variation in symptoms experienced by women with Interstitial Cystitis/Bladder Pain Syndrome, American Urogynecologic Society (AUGS) Pelvic Floor Disorders (PFD) Week, October 6-10, Vancouver, Canada

BPS Utilizing Veterans Health Administration Data

Anger JT, Dallas KB, Bresee CB, De Hoedt A, Haywood K, Barbour KE, Hoggatt K, Goodman M, Kim J, Freedland S, National Prevalence of IC/BPS Utilizing Veterans Health Administration Data, New England Journal of Medicine, in review

This CDC-funded study estimates the prevalence of IC to be about 1% (1.4% in women and 0.55% in men) nationally and uses robust and rigorous diagnostic criteria.

Anger, J, Dallas, K, Bresee CB, De Hoedt A, Haywood K, Barbour KE, Hoggatt K, Goodman M, Kim J, Freedland S. Estimated National Prevalence of IC/BPS Utilizing Veterans Health Administration Data. American Urological Association’s 2020 Annual Meeting, May 15-19. Washington, DC, USA

In terms of comorbidities, the CDC-funded study reports an estimated 2.72 comorbidities per patient with IC (significantly higher than patients without IC).

In terms of comorbidities, the CDC-funded study reports an estimated 2.72 comorbidities per patient with IC (significantly higher than patients without IC). 

Laden BF, Hoedt AD, Scharfenberg A, Saxena R, Senechal JF, Bresee CT, Barbour KE, Kim J, Freedland SJ, Anger JT. Comorbid Conditions in a Nationwide, Heterogenous Population of Veterans with Interstitial Cystitis/Bladder Pain Syndrome. American Urology Association Conference. May 3rd-6th, 2019 in Chicago, IL, USA.

The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population

Skove SL, Howard LE, Senechal J, Hoedt AD, Bresee C, Cunningham TJ, Barbour KE, Kim J, Freedland SJ, Anger JT. The Misdiagnosis of Interstitial Cystitis/Bladder Pain Syndrome in a VA Population. Neurourol Urodyn. 2019 Sep;38(7):1966-1972, PMID:31302944

https://pubmed.ncbi.nlm.nih.gov/31302944/

Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis

Shahid M, Yeon A, Kim J (2020) Metabolomic and Lipidomic Approaches to Identify Biomarkers for Bladder Cancer and Interstitial Cystitis, Molecular Medicine Report, 22: 5003-5011, DOI : 10.3892/mmr.2020.11627

Omics approaches to understanding interstitial cystitis/painful bladder syndrome

You Y, Yang W, Anger JT, Freeman MR, Kim J.* (2012) Omics approaches to understanding interstitial cystitis/painful bladder syndrome/bladder pain syndrome. International Neurourology Journal, 16(4):159-68. PMID: 23346481 PMCID: PMC3547176  *corresponding author

Integration analysis of quantitative proteomics and transcriptomics data identifies potential targets of frizzled-8 protein-related antiproliferative factor in vivo

Yang W, Kim Y, Kim T, Keay SK, Kim KP, Steen H, Freeman MR, Hwang D, Kim J*. (2012) Integration analysis of quantitative proteomics and transcriptomics data identifies potential targets of frizzled-8 protein-related antiproliferative factor in vivo, British Journal of Urology International, 110(11c):E1138-E1146, PMID: 22738385 PMCID: PMC3461241  *corresponding author

A synthetic form of frizzled 8-associated antiproliferative factor

Kim J*, Keay SK, You S, Loda M, Freeman MR. (2012) A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2, PLoS ONE, 7(12):e50392. PMID: 23236372 PMCID: PMC3516501 *corresponding author

Alterations in the DNA methylation patterns of Calca, Timp3, Mmp2, and Igf2r associated with chronic cystitis in a cyclosphosphamide-induced mouse model

Choi IS, Yu KK, Kim J, Guzman E, Weisenberger DJ, Oghamian S, Kim HJ, Lee KH, Carroll C, Trinh BN, Kim M, Houshdaran S, Laird PW, Jones PA, Warburton D, Liang G, and Koh CJ.  (2013) Alterations in the DNA methylation patterns of Calca, Timp3, Mmp2, and Igf2r associated with chronic cystitis in a cyclosphosphamide-induced mouse model.   Urology, 82(1):253.e9-15, PMID: 23806407 PMCID: PMC3697025

Metabolomics insights into pathophysiological mechanisms of interstitial cystitis

Fiehn O, Kim J. (2014) Metabolomics insights into pathophysiological mechanisms of interstitial cystitis. International Neurourology Journal, 18(3):106-14 PMID: 25279237 PMCID: PMC4180160

Urinary Metabolite Profiling Combined with Computational Analysis Predicts Interstitial Cystitis-Associated Candidate Biomarkers

Wen H, Lee T, You S, Park SH, Song H, Eilber K, Anger JT, Freeman MR, Park S*, Kim J (2015) Urinary Metabolite Profiling Combined with Computational Analysis Predicts Interstitial Cystitis-Associated Candidate Biomarkers. Journal of Proteome Research, 14(1):541-8. PMID: 25353990 PMCID: PMC4286193   *co-corresponding authors PMC4180160

Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis

Kind T, Cho E, Park T, Deng N, Liu Z, Lee T, Fiehn O, Kim J (2016) Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis, Scientific Reports, 6:39227, PMID: 27976711 PMCID: PMC5156939

Differential perturbation of the interstitial cystitis-associated genes of bladder and urethra in rat model

Choi BH, You S, Park CS, Cho EH, Park TD, Kim S, Kim YJ, Lee T, Kim J (2017) Differential perturbation of the interstitial cystitis-associated genes of bladder and urethra in rat model, Cell Cycle, 16(8):749-758, PMID: 28278053 PMCID: PMC5405721

Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases

Chen Z, Kim J. (2016) Urinary proteomics and metabolomics studies to monitor bladder  health and urological diseases, BMC Urology, 16(1):11, PMID: 27000794

Are We Ready to Use the Omics Strategies for Precision Medicine? Special Issue, Omics Approaches to Understand Bladder Diseases and Beyond

Kim J (2016) Are We Ready to Use the Omics Strategies for Precision Medicine? Special Issue, Omics Approaches to Understand Bladder Diseases and Beyond, International Neurourology Journal. 20(Suppl 2):S65-67. PMID: 27915470, PMCID: PMC5169089

Waste Product or Biologically Active Tissue?

Urinology Think Tank Study Group: Barasch J, Bavendam T, Birder L, Buffington CA, Campeau L, Dmochowski R, Hewitt S, Hill W, Hoshizaki D, Kim J, Klein J, Norton JM, Seed P, Williams J, Yu W, and Star R  (2017) Urine: Waste Product or Biologically Active Tissue? Neurourology and Urodynamics (in press)(manuscript is attached)